No one believes that H.R. 3, the Democratic House leadership’s drug pricing bill, will be enacted into law , but that hasn’t stopped it from precipitating frenzied debates. The bill has become a strawman for advocates...
...oligonucleotide therapy for Parkinson's disease patients carrying a mutation in GBA, Chamishi Therapeutics launched from Q-State Biosciences Inc.... ...nuclear receptor subfamily 3 group E member 3
BioCentury Staff
AbbVie Inc.
Allergan Inc.
Simcere Pharmaceutical Group
JW Pharmaceutical Corp.
Q-State Biosciences Inc.
CanSino...
...said disease-in-a-dish models had predicted effects correctly in control individuals, and noted that he co-founded Q-State Biosciences Inc.... ...General Hospital, Boston, Mass. Microbot Medical Ltd., Yokneam, Israel Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Q-State Biosciences Inc....
Quebec announced the Quebec Biopharmaceutical Strategy , a program to provide development support for biotech and biopharmaceutical companies in the province. The government is providing C$122.8 million ($114 million) to fund the program. Separately, the Kansas...
No one believes that H.R. 3, the Democratic House leadership’s drug pricing bill, will be enacted into law , but that hasn’t stopped it from precipitating frenzied debates. The bill has become a strawman for advocates...
...oligonucleotide therapy for Parkinson's disease patients carrying a mutation in GBA, Chamishi Therapeutics launched from Q-State Biosciences Inc.... ...nuclear receptor subfamily 3 group E member 3
BioCentury Staff
AbbVie Inc.
Allergan Inc.
Simcere Pharmaceutical Group
JW Pharmaceutical Corp.
Q-State Biosciences Inc.
CanSino...
...said disease-in-a-dish models had predicted effects correctly in control individuals, and noted that he co-founded Q-State Biosciences Inc.... ...General Hospital, Boston, Mass. Microbot Medical Ltd., Yokneam, Israel Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Q-State Biosciences Inc....
Quebec announced the Quebec Biopharmaceutical Strategy , a program to provide development support for biotech and biopharmaceutical companies in the province. The government is providing C$122.8 million ($114 million) to fund the program. Separately, the Kansas...